Serum fibroblast growth factor 23 for early detection of acute kidney injury in critical illness.

ABSTRACT:

Background

Serum fibroblast growth factor 23 (FGF23) is associated with acute kidney injury (AKI) and mortality in patients with critical illnesses. However, the accurate predictive performance of FGF23 on AKI remains inconclusive.

Methods

Meta-analysis was performed using data sources including PubMed, Web of Science, EMBASE, and Cochrane (until June 1, 2021). Cohort or observational studies including patients with AKI and serum FGF23 level as the index test were included. The primary outcome was the AKI detective accuracy. This study has been registered in PROSPERO (CRD42021249930).

Results

Eleven studies with 1946 patients in seven countries were included. Across all settings, the sensitivity and specificity for serum FGF23 levels to predict AKI were 82% (95% CI, 6

SUBMITTER: Sun S 

PROVIDER: S-EPMC8661170 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature